NEUPHORIA THERAPEUTICS INC (NEUP) Stock Overview
USA - NASDAQ:NEUP - US64136E1029 - Common Stock
NEUP Key Statistics, Chart & Performance
The current stock price of NEUP is 6.24 USD. In the past month the price decreased by -49.31%.
NEUP Latest News, Press Relases and Analysis
NEUP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About NEUP
Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Company Info
NEUPHORIA THERAPEUTICS INC
100 Summit Dr
Burlington MASSACHUSETTS US
Employees: 7
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What does NEUP do?
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
What is the current price of NEUP stock?
The current stock price of NEUP is 6.24 USD. The price increased by 54.07% in the last trading session.
What is the dividend status of NEUPHORIA THERAPEUTICS INC?
NEUP does not pay a dividend.
What is the ChartMill rating of NEUPHORIA THERAPEUTICS INC stock?
NEUP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is NEUPHORIA THERAPEUTICS INC (NEUP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NEUP.
Can you provide the number of employees for NEUPHORIA THERAPEUTICS INC?
NEUPHORIA THERAPEUTICS INC (NEUP) currently has 7 employees.
Can you provide the short interest for NEUP stock?
The outstanding short interest for NEUPHORIA THERAPEUTICS INC (NEUP) is 1.57% of its float.
NEUP Technical Analysis
NEUP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEUP. The financial health of NEUP is average, but there are quite some concerns on its profitability.
NEUP Financial Highlights
Over the last trailing twelve months NEUP reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -130% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.29% | ||
| ROE | -1.95% | ||
| Debt/Equity | 0 |
NEUP Forecast & Estimates
9 analysts have analysed NEUP and the average price target is 46.58 USD. This implies a price increase of 646.47% is expected in the next year compared to the current price of 6.24.
For the next year, analysts expect an EPS growth of -104017.17% and a revenue growth 686792% for NEUP